New hope for rare cancer: drug trial targets adenoid cystic carcinoma

NCT ID NCT05074940

First seen May 12, 2026 · Last updated May 14, 2026 · Updated 1 time

Summary

This phase 2 study tests the drug amivantamab in 21 people with recurrent or metastatic adenoid cystic carcinoma, a rare salivary gland cancer. The main goal is to see if the drug shrinks tumors or slows disease progression. Participants must have cancer that has worsened recently and cannot be treated with curative intent.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SALIVARY GLAND CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Rogel Cancer Center - University of Michigan Health

    Ann Arbor, Michigan, 48109, United States

  • UC San Diego Moores Cancer Center

    La Jolla, California, 92093, United States

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45219, United States

  • Washington University - School of Medicine in St. Louis

    St Louis, Missouri, 63130, United States

Conditions

Explore the condition pages connected to this study.